Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 17;3(4):309-321.
doi: 10.3138/canlivj-2020-0013. eCollection 2020 Fall.

An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic

Mayur Brahmania  1 , Stephen Congly  2 , Saumya Jayakumar  3 , Carla S Coffin  2 , Kelly W Burak  2 , Jordan J Feld  4
Affiliations

An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic

Mayur Brahmania et al. Can Liver J. .

Abstract

Coronavirus disease 2019 (COVID-19) has challenged how care is delivered to patients with chronic liver disease (CLD). In an attempt to update Canadian health care practitioners taking care of individuals with CLD, the Canadian Association for the Study of the Liver (CASL) hosted a webinar on May 7, 2020, with more than 120 participants. The resultant article is a partnership between members of CASL's executive and education committees to provide best practice management principles on liver disease during COVID-19 to the broader hepatology community.

Keywords: CASL; COVID-19; chronic liver disease.

PubMed Disclaimer

Conflict of interest statement

Dr Brahmania reports personal fees from Roche, Eisai, and Abbvie; grants and personal fees from Merck; and grants from Allergan. Dr Congly reports grants from Gilead Sciences, Boehringer Ingelheim, Genfit, Allergan, and Sequana Medical and personal fees from Intercept Pharmaceuticals and Eisai. Dr Coffin reports grants for the Canadian HBV Network from Janssen; grants from Glaxo Smith Kline and Gilead Sciences; and personal fees from Springbank Pharmaceuticals and Altimmune. Dr Jayakumar and Dr Burak have no disclosures to report. Dr Feld reports receiving grants and consulting fees from AbbVie, Arbutus Biopharma, Enanta Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, and Roche.

Figures

Figure 1:
Figure 1:
Mechanisms of liver injury induced by COVID-19 infection
Figure 2:
Figure 2:
Management of esophageal varices during COVID-19
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. World Health Organization. https://www.who.int/ (Accessed 14 May 2020).
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. 10.1016/S0140-6736(20)30211-7. - DOI - PMC - PubMed
    1. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236), 1569–78. 10.1016/S0140-6736(20)31022-9. - DOI - PMC - PubMed
    1. Sultan S, Lim J, Altayar O, et al. AGA Institute rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic. Gastroenterology. 2020; 159(2), P739–758. 10.1053/j.gastro.2020.03.072. Medline: - DOI - PMC - PubMed

LinkOut - more resources